January 1994 in “European Journal of Cancer” The European School of Oncology organized various educational events in 1994, highlighting important cancer research findings.
July 2024 in “Journal of Investigative Dermatology” ATR04-484 ointment shows promise for treating skin issues from cancer therapies.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib effectively promotes hair regrowth in severe and very severe alopecia areata.
2 citations
,
January 2022 in “Journal of Cosmetic Dermatology” QR678 Neo® is a safe and effective treatment for hair loss in men and women.
October 2024 in “Asian Journal of Pharmaceutical and Clinical Research” Topical methotrexate is more effective and as safe as betamethasone for treating alopecia areata.
January 2018 in “Figshare” Ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata.
15 citations
,
December 2019 in “European Journal of Dermatology” Low-dose tofacitinib is effective and cheaper for severe alopecia areata.
66 citations
,
December 2018 in “Dermatology” Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.
November 2024 in “Journal of Investigative Dermatology” Serotonin helps wounds heal faster.
5 citations
,
January 2007 in “Immunopharmacology and Immunotoxicology” 17β-Estradiol boosts allergic reactions and slows thymus aging in mice.
1 citations
,
April 2018 in “Lasers in Surgery and Medicine” New treatments and technologies in laser medicine show promise for improving skin conditions, fat reduction, cancer treatment, wound healing, and hair restoration.
Activating certain hair follicle cells could prevent hair loss from cancer treatments.
April 2025 in “The Journal of Dermatology” Janus kinase inhibitors may help treat cutaneous T-cell lymphoma, but more research is needed.
130 citations
,
February 2018 in “Journal of Investigative Dermatology” Tofacitinib may help treat severe hair loss, but more research is needed.
1 citations
,
May 2025 in “The Journal of Dermatology” Increased regulatory T cell activity may lead to better outcomes in acute diffuse and total alopecia.
Ion sequential therapy improves heart function after a heart attack.
February 2024 in “Journal of cutaneous and aesthetic surgery” The combined treatment helps improve severe hair loss and reduces the need for other medications.
4 citations
,
January 2001 in “Archives of Biochemistry and Biophysics” Activated ras can protect kidney cells from a certain substance that causes cell death.
February 2023 in “Military Medical Science Letters” Platelet-rich plasma treatments reduce knee osteoarthritis inflammation, with pure PRP being more effective.
September 2023 in “Journal of the American Academy of Dermatology”
February 2026 in “Zenodo (CERN European Organization for Nuclear Research)” Triamcinolone is more effective for hair regrowth in alopecia areata, but Vitamin D also helps, especially if levels are low.
February 2026 in “Zenodo (CERN European Organization for Nuclear Research)” Triamcinolone is more effective for hair regrowth in alopecia areata, but Vitamin D also helps, especially if levels are low.
September 2023 in “Journal of the American Academy of Dermatology” Ixekizumab is safe for long-term use with low rates of major heart-related events.
April 2025 in “Frontiers in Pharmacology” Canagliflozin helps overcome progestin resistance in certain endometrial cancer cells.
1 citations
,
August 2022 in “Frontiers in Medicine” ALRV5XR effectively promotes hair regrowth in both men and women through different mechanisms.
68 citations
,
August 2009 in “American Journal of Medical Genetics Part A” A new classification for trichothiodystrophy helps identify genetic causes and potential treatments.
5-ARI therapy may help prevent prostate cancer progression.
10 citations
,
August 2019 in “European Journal of Dermatology” The document did not conclude on apremilast's effectiveness for severe alopecia areata.
9 citations
,
October 2021 in “International Journal of Dermatology” Tofacitinib is effective and safe for treating severe hair loss in a Saudi population.
February 2026 in “Frontiers in Immunology” Tralokinumab for atopic dermatitis may cause eye issues and skin reactions, needing careful monitoring.